Back HIV/AIDS HIV/AIDS Topics HIV Treatment

CROI 2014: Early Treatment Reduces Viral Reservoirs but Does Not Prevent Rebound

Antiretroviral therapy started during the first several days after infection limited dissemination of an HIV-like virus throughout the body and establishment of cellular and tissue reservoirs in monkeys, though it did not prevent the virus from coming back after stopping treatment, according to research presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston.

alt

Read more:

CROI 2014: Early Antiretroviral Therapy May Limit Gut Damage and Immune Activation

Starting antiretroviral therapy (ART) at the earliest stage of HIV infection can help prevent immune cell dysregulation that contributes to destruction of the gut lining and promotes systemic immune over-activation, according to a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston.

alt

Read more:

CROI 2014: Long-Acting HIV Drugs for Maintenance Therapy [VIDEO]

A combination of 2 antiretrovirals used as maintenance therapy for people with undetectable viral load -- the next-generation integrase inhibitor GSK1265744 and the NNRTI rilpivirine (Edurant) -- led to continued viral suppression in more than 80% of treated patients, according to a report at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston.

alt

This study was done in preparation for a trial of long-acting injectable formulations of GSK1265744 (or GSK744 for short) and rilpivirine. These findings suggest that these drugs may be feasible for long-term maintenance therapy, though concerns remain about development of resistance under certain circumstances.

[David Margolis, CROI press conference, March 5, 2014]

See also: CROI 2014: Novel 2-Drug Maintenance Combo Works Well, Stage Set for Long-lasting Injectable [study report]

3/10/14

Reference

D Margolis, C Brinson, J Eron, et al. 744 and Rilpivirine as Two-Drug Oral Maintenance Therapy: LAI116482 (LATTE) Week 48 Results. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston, March 3-6. Abstract 91LB.

CROI 2014: New NNRTI Doravirine Matches Efavirenz for First-line HIV Treatment

The next-generation non-nucleoside reverse transcriptase inhibitor doravirine (formerly MK-1439) showed potent antiretroviral activity and good tolerability in combination with tenofovir/emtricitabine (the drugs in Truvada) in a dose-finding study presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston.

alt

Read more:

CROI 2014: Raltegravir Works as Well as Tenofovir for HIV Treatment [VIDEO]

A NRTI-sparing first-line antiretroviral regimen of raltegravir (Isentress) plus ritonavir-boosted darunavir (Prezista) worked as well as standard therapy containing tenofovir/emtricitabine (the drugs in Truvada), according to results from the NEAT 001 trial presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston.

alt

[Francois Raffi, CROI press conference, March 5, 2014]

See also: CROI 2014: Raltegravir Plus Boosted Darunavir Is Safe and Effective for First-line ART [study report]

3/10/14

Reference

F Raffi, AG Babiker, L Richert, et al. First-Line RAL + DRV/r Is Non-Inferior To TDF/FTC + DRV/r: The NEAT001/ANRS143 Randomised Trial. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston, March 3-6. Abstract 84LB.

CROI 2014: Novel 2-Drug Maintenance Combo Works Well, Stage Set for Long-lasting Injectables

An oral combination of 2 antiretroviral drugs -- the non-nucleoside reverse transcriptase inhibitor rilpivirine (Edurant, also in Complera or Eviplera) and the new integrase inhibitor GSK1265744 -- was at least as effective as a standard NRTIs-plus-efavirenz triple combination in keeping viral load undetectable, according to a report presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston.

alt

Read more:

Coverage of the 2014 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014), March 3-6, 2014, in Boston.

Conference highlights include new treatments for hepatitis C, HIV experimental therapies and treatment strategies, HIV cure research, HIV-related conditions, treatment as prevention and PrEP, and HIV/HCV coinfection.

Full listing by topic

Selected presentations and slide webcasts 

3/9/14

alt